Investigational Drug Information for Setanaxib
✉ Email this page to a colleague
What is the development status for investigational drug Setanaxib?
Setanaxib is an investigational drug.
There have been 3 clinical trials for Setanaxib.
The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2021.
The most common disease conditions in clinical trials are Carcinoma, Squamous Cell, Carcinoma, and Liver Cirrhosis, Biliary. The leading clinical trial sponsors are Genkyotex Suisse SA, Genkyotex SA, and [disabled in preview].
Summary for Setanaxib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 40 |
| WIPO Patent Applications | 37 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 1 (2021-10-01) |
| Vendors | 0 |
Recent Clinical Trials for Setanaxib
| Title | Sponsor | Phase |
|---|---|---|
| A Phase 2, Randomised Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic SCCHN | Genkyotex Suisse SA | Phase 2 |
| A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness | Genkyotex Suisse SA | Phase 2/Phase 3 |
| Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects | Genkyotex SA | Phase 1 |
Clinical Trial Summary for Setanaxib
Top disease conditions for Setanaxib
Top clinical trial sponsors for Setanaxib
US Patents for Setanaxib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
